PMID- 30862641
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20190409
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 364
DP  - 2019 Mar 12
TI  - Sixty seconds on . . . reversing type 2 diabetes.
PG  - l1128
LID - 10.1136/bmj.l1128 [doi]
FAU - Iacobucci, Gareth
AU  - Iacobucci G
AD  - The BMJ.
LA  - eng
PT  - Journal Article
DEP - 20190312
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
EDAT- 2019/03/14 06:00
MHDA- 2019/03/14 06:01
CRDT- 2019/03/14 06:00
PHST- 2019/03/14 06:00 [entrez]
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2019/03/14 06:01 [medline]
AID - 10.1136/bmj.l1128 [doi]
PST - epublish
SO  - BMJ. 2019 Mar 12;364:l1128. doi: 10.1136/bmj.l1128.

PMID- 30868654
OWN - NLM
STAT- Publisher
LR  - 20190408
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2019 Mar 13
TI  - Exploring organizational support for the provision of structured self-management 
      education for people with Type 2 diabetes: findings from a qualitative study.
LID - 10.1111/dme.13946 [doi]
AB  - AIM: To explore the organizational context in which Type 2 diabetes structured
      group education is provided. METHODS: Four Clinical Commissioning Groups in
      England providing Type 2 diabetes structured self-management education
      participated in a qualitative study exploring the context for provision of that
      education. Using UK National Diabetes Audit returns, two Clinical Commissioning
      Groups were selected that had non-attendance rates of </=25%, and two that had
      non-attendance rates of >/=50%. Between May 2016 and August 2017, 20 interviews
      were conducted with Clinical Commissioning Group staff including: commissioners, 
      healthcare professionals, managers, general practitioners and diabetes educators.
      Data gathering was prolonged as it proved challenging to engage with healthcare
      staff as a result of frequent local restructuring and service disruption.
      RESULTS: Local audits revealed discrepancies in basic data such as referral and
      attendance numbers compared with national audit data. There was a commonality in 
      the themes identified from interviews: diabetes education was rarely embedded in 
      service structure; where education uptake was poor, a lack of central support to 
      delivery teams was noticeable; and where education uptake was positive, delivery 
      teams were actively engaged, sometimes relying on enthusiastic individuals. Both 
      situations put the local sustainability of diabetes education at risk.
      CONCLUSIONS: There appears to be a link between attendance rates and
      organizational issues, therefore, when considering how to increase attendance
      rates, the state of the diabetes education infrastructure should be reviewed.
      Good uptake of diabetes education can be too reliant on the enthusiastic
      commitment of small teams or individuals delivering the education.
CI  - (c) 2019 Diabetes UK.
FAU - Carey, M E
AU  - Carey ME
AUID- ORCID: http://orcid.org/0000-0001-5672-767X
AD  - Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust,
      Leicester, UK.
AD  - College of Life Sciences, University of Leicester, Leicester, UK.
FAU - Agarwal, S
AU  - Agarwal S
AD  - College of Life Sciences, University of Leicester, Leicester, UK.
FAU - Horne, R
AU  - Horne R
AD  - Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust,
      Leicester, UK.
FAU - Davies, M
AU  - Davies M
AD  - Belfast Health and Social Care Trust, Belfast, UK.
FAU - Slevin, M
AU  - Slevin M
AUID- ORCID: http://orcid.org/0000-0003-0977-8209
AD  - School of Nursing, Ulster University, Coleraine, UK.
FAU - Coates, V
AU  - Coates V
AUID- ORCID: http://orcid.org/0000-0002-8069-2961
AD  - School of Nursing, Ulster University, Coleraine, UK.
AD  - Western Health and Social Care Trust, Londonderry, UK.
LA  - eng
GR  - BDA:11/0004632/Diabetes UK/United Kingdom
PT  - Journal Article
DEP - 20190313
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2019/03/15 06:00
MHDA- 2019/03/15 06:00
CRDT- 2019/03/15 06:00
PHST- 2019/03/08 00:00 [accepted]
PHST- 2019/03/15 06:00 [pubmed]
PHST- 2019/03/15 06:00 [medline]
PHST- 2019/03/15 06:00 [entrez]
AID - 10.1111/dme.13946 [doi]
PST - aheadofprint
SO  - Diabet Med. 2019 Mar 13. doi: 10.1111/dme.13946.

PMID- 30862683
OWN - NLM
STAT- Publisher
LR  - 20190313
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2019 Mar 12
TI  - Cardiac Autonomic Function is Associated With Myocardial Flow Reserve in Type 1
      Diabetes.
LID - db181313 [pii]
LID - 10.2337/db18-1313 [doi]
AB  - The link between cardiac autonomic neuropathy and risk of cardiovascular disease 
      is highlighted as an area in which research is needed. This study was undertaken 
      to evaluate the association between measures of cardiac autonomic function and
      cardiac vascular function in type 1 diabetes using new and sensitive
      methods.Cross-sectional study in type 1 diabetes, stratified by normoalbuminuria 
      (n=30) and macroalbuminuria (n=30), and in healthy controls (n=30). Cardiac
      autonomic function was evaluated using heart rate variability (HRV) indices,
      cardiovascular autonomic reflex tests (CARTs) and cardiac
      (123)I-metaiodobenzylguanidine (MIBG) imaging. Cardiac vascular function was
      assessed as myocardial flow reserve (MFR) measured by cardiac
      (82)Rb-positron-emission-tomography/computed-tomography.The measures of cardiac
      autonomic function (except low-frequency-to-high-frequency ratio and the Valsalva
      test ratio) were positively correlated to MFR in unadjusted analysis. All the HRV
      indices lost significance after adjustment for age and heart rate. After further 
      adjustment for relevant cardiovascular risk factors, the late
      heart-to-mediastinum ratio directly measuring the function of adrenergic
      receptors and sympathetic integrity (from the MIBG scintigraphy) and the 30-to-15
      ratio (a CART), remained positively associated with MFR (p </=0.04).Cardiac
      autonomic dysfunction including loss of cardiac sympathetic integrity in type 1
      diabetes is associated with and may contribute to impaired myocardial blood flow 
      regulation.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Zobel, Emilie H
AU  - Zobel EH
AD  - Steno Diabetes Center Copenhagen, Niels Steensens Vej 2, 2820 Gentofte, Denmark
      emilie.hein.zobel@regionh.dk.
FAU - Hasbak, Philip
AU  - Hasbak P
AD  - Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for
      Molecular Imaging, Rigshospitalet, Copenhagen, Denmark.
FAU - Winther, Signe A
AU  - Winther SA
AD  - Steno Diabetes Center Copenhagen, Niels Steensens Vej 2, 2820 Gentofte, Denmark.
FAU - Stevns, Christian
AU  - Stevns C
AD  - Steno Diabetes Center Copenhagen, Niels Steensens Vej 2, 2820 Gentofte, Denmark.
FAU - Fleischer, Jesper
AU  - Fleischer J
AD  - Steno Diabetes Center Aarhus, Aarhus, Denmark.
FAU - von Scholten, Bernt J
AU  - von Scholten BJ
AD  - Steno Diabetes Center Copenhagen, Niels Steensens Vej 2, 2820 Gentofte, Denmark.
FAU - Holmvang, Lene
AU  - Holmvang L
AD  - Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
FAU - Kjaer, Andreas
AU  - Kjaer A
AD  - Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for
      Molecular Imaging, Rigshospitalet, Copenhagen, Denmark.
FAU - Rossing, Peter
AU  - Rossing P
AD  - Steno Diabetes Center Copenhagen, Niels Steensens Vej 2, 2820 Gentofte, Denmark.
AD  - University of Copenhagen, Copenhagen, Denmark.
FAU - Hansen, Tine W
AU  - Hansen TW
AD  - Steno Diabetes Center Copenhagen, Niels Steensens Vej 2, 2820 Gentofte, Denmark.
LA  - eng
PT  - Journal Article
DEP - 20190312
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2019/03/14 06:00
MHDA- 2019/03/14 06:00
CRDT- 2019/03/14 06:00
PHST- 2018/12/13 00:00 [received]
PHST- 2019/03/06 00:00 [accepted]
PHST- 2019/03/14 06:00 [entrez]
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2019/03/14 06:00 [medline]
AID - db18-1313 [pii]
AID - 10.2337/db18-1313 [doi]
PST - aheadofprint
SO  - Diabetes. 2019 Mar 12. pii: db18-1313. doi: 10.2337/db18-1313.

PMID- 30862678
OWN - NLM
STAT- Publisher
LR  - 20190313
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2019 Mar 12
TI  - Diabetes-Induced DUSP4 Reduction Promotes Podocyte Dysfunction and Progression of
      Diabetic Nephropathy.
LID - db180837 [pii]
LID - 10.2337/db18-0837 [doi]
AB  - Diabetic nephropathy (DN) remains the leading cause of end-stage renal disease.
      Hyperglycemia-induced podocyte dysfunction is a major contributor of renal
      function impairment in DN. Previous studies showed that activation of
      mitogen-activated protein kinase (MAPK) in diabetes promotes podocyte dysfunction
      and cell death. Dual specificity phosphatase (DUSP) are a family of phosphatases 
      mainly responsible for MAPK inhibition. In this study, we demonstrated that
      diabetes and high glucose exposure decreased DUSP4 expression in cultured
      podocytes and glomeruli. Diabetes-induced DUSP4 reduction enhanced p38 and JNK
      activity, and podocyte dysfunction. The overexpression of DUSP4 prevented the
      activation of p38, JNK, caspase 3/7 activity and NOX4 expression induced by high 
      glucose level exposure. Deletion of DUSP4 exacerbated albuminuria and increased
      mesangial expansion and glomerular fibrosis in diabetic mice. These morphological
      changes were associated with profound podocyte foot process effacement, cell
      death and sustained p38 and JNK activation. Moreover, inhibition of protein
      kinase C-delta prevented DUSP4 expression decline and p38/JNK activation in
      podocytes and renal cortex of diabetic mice. Analysis of DUSP4 expression in
      renal cortex of diabetic patients revealed that decreased DUSP4 mRNA expression
      correlated with reduced eGFR (<60 ml/min/1.73 m(2)). Thus, this study
      demonstrates that preserving DUSP4 expression could protect against podocyte
      dysfunction and preserve glomerular function in DN.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Denhez, Benoit
AU  - Denhez B
AD  - From the Research Center of the Centre Hospitalier Universitaire de Sherbrooke
      and.
FAU - Rousseau, Marina
AU  - Rousseau M
AD  - From the Research Center of the Centre Hospitalier Universitaire de Sherbrooke
      and.
FAU - Dancosst, David-Alexandre
AU  - Dancosst DA
AD  - From the Research Center of the Centre Hospitalier Universitaire de Sherbrooke
      and.
FAU - Lizotte, Farah
AU  - Lizotte F
AD  - From the Research Center of the Centre Hospitalier Universitaire de Sherbrooke
      and.
FAU - Guay, Andreanne
AU  - Guay A
AD  - From the Research Center of the Centre Hospitalier Universitaire de Sherbrooke
      and.
FAU - Auger-Messier, Mannix
AU  - Auger-Messier M
AD  - From the Research Center of the Centre Hospitalier Universitaire de Sherbrooke
      and.
AD  - Division of Cardiology.
FAU - Cote, Anne Marie
AU  - Cote AM
AD  - From the Research Center of the Centre Hospitalier Universitaire de Sherbrooke
      and.
AD  - Nephrology and.
FAU - Geraldes, Pedro
AU  - Geraldes P
AD  - From the Research Center of the Centre Hospitalier Universitaire de Sherbrooke
      and Pedro.Geraldes@USherbrooke.ca.
AD  - Endocrinology, Department of Medicine, Universite de Sherbrooke, Quebec, Canada.
LA  - eng
PT  - Journal Article
DEP - 20190312
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2019/03/14 06:00
MHDA- 2019/03/14 06:00
CRDT- 2019/03/14 06:00
PHST- 2018/08/01 00:00 [received]
PHST- 2019/02/25 00:00 [accepted]
PHST- 2019/03/14 06:00 [entrez]
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2019/03/14 06:00 [medline]
AID - db18-0837 [pii]
AID - 10.2337/db18-0837 [doi]
PST - aheadofprint
SO  - Diabetes. 2019 Mar 12. pii: db18-0837. doi: 10.2337/db18-0837.

PMID- 30877090
OWN - NLM
STAT- In-Data-Review
LR  - 20190407
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 4
DP  - 2019 Apr
TI  - Long-term Effects of Metformin on Diabetes Prevention: Identification of
      Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes
      Prevention Program Outcomes Study.
PG  - 601-608
LID - 10.2337/dc18-1970 [doi]
AB  - OBJECTIVE: We examined the effects of metformin on diabetes prevention and the
      subgroups that benefited most over 15 years in the Diabetes Prevention Program
      (DPP) and its follow-up, the Diabetes Prevention Program Outcomes Study (DPPOS). 
      RESEARCH DESIGN AND METHODS: During the DPP (1996-2001), adults at high risk of
      developing diabetes were randomly assigned to masked placebo (n = 1,082) or
      metformin 850 mg twice daily (n = 1,073). Participants originally assigned to
      metformin continued to receive metformin, unmasked, in the DPPOS (2002-present). 
      Ascertainment of diabetes development was based on fasting or 2-h glucose levels 
      after an oral glucose tolerance test or on HbA1c. Reduction in diabetes incidence
      with metformin was compared with placebo in subgroups by hazard ratio (HR) and
      rate differences (RDs). RESULTS: During 15 years of postrandomization follow-up, 
      metformin reduced the incidence (by HR) of diabetes compared to placebo by 17% or
      36% based on glucose or HbA1c levels, respectively. Metformin's effect on the
      development of glucose-defined diabetes was greater for women with a history of
      prior gestational diabetes mellitus (GDM) (HR 0.59, RD -4.57 cases/100
      person-years) compared with parous women without GDM (HR 0.94, RD -0.38 cases/100
      person-years [interaction P = 0.03 for HR, P = 0.01 for RD]). Metformin also had 
      greater effects, by HR and RD, at higher baseline fasting glucose levels. With
      diabetes development based on HbA1c, metformin was more effective in subjects
      with higher baseline HbA1c by RD, with metformin RD -1.03 cases/100 person-years 
      with baseline HbA1c <6.0% (42 mmol/mol) and -3.88 cases/100 person-years with
      6.0-6.4% (P = 0.0001). CONCLUSIONS: Metformin reduces the development of diabetes
      over 15 years. The subsets that benefitted the most include subjects with higher 
      baseline fasting glucose or HbA1c and women with a history of GDM.
CI  - (c) 2019 by the American Diabetes Association.
CN  - Diabetes Prevention Program Research Group
LA  - eng
GR  - U01 DK048489/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
PMC - PMC6429636
IR  - Nathan DM
FIR - Nathan, David M
IR  - Knowler WC
FIR - Knowler, William C
IR  - Edelstein S
FIR - Edelstein, Sharon
IR  - Crandall JP
FIR - Crandall, Jill P
IR  - Dabelea D
FIR - Dabelea, Dana
IR  - Goldberg RB
FIR - Goldberg, Ronald B
IR  - Kahn SE
FIR - Kahn, Steven E
IR  - Mather KJ
FIR - Mather, Kieren J
IR  - Trandafirescu G
FIR - Trandafirescu, Gilda
IR  - Walker EA
FIR - Walker, Elizabeth A
IR  - Temprosa M
FIR - Temprosa, Marinella
IR  - Bray GA
FIR - Bray, George A
IR  - Gadde K
FIR - Gadde, Kishore
IR  - Chatellier A
FIR - Chatellier, Annie
IR  - Arceneaux J
FIR - Arceneaux, Jennifer
IR  - Dragg A
FIR - Dragg, Amber
IR  - Duncan C
FIR - Duncan, Crystal
IR  - Greenway FL
FIR - Greenway, Frank L
IR  - Hsia D
FIR - Hsia, Daniel
IR  - Levy E
FIR - Levy, Erma
IR  - Lockett M
FIR - Lockett, Monica
IR  - Ryan DH
FIR - Ryan, Donna H
IR  - Ehrmann D
FIR - Ehrmann, David
IR  - Matulik MJ
FIR - Matulik, Margaret J
IR  - Czech K
FIR - Czech, Kirsten
IR  - DeSandre C
FIR - DeSandre, Catherine
IR  - Goldstein BJ
FIR - Goldstein, Barry J
IR  - Furlong K
FIR - Furlong, Kevin
IR  - Smith KA
FIR - Smith, Kellie A
IR  - Wildman W
FIR - Wildman, Wendi
IR  - Pepe C
FIR - Pepe, Constance
IR  - Calles J
FIR - Calles, Jeanette
IR  - Ojito J
FIR - Ojito, Juliet
IR  - Castillo-Florez S
FIR - Castillo-Florez, Sumaya
IR  - Giannella A
FIR - Giannella, Anna
IR  - Lara O
FIR - Lara, Olga
IR  - Veciana B
FIR - Veciana, Beth
IR  - Haffner SM
FIR - Haffner, Steven M
IR  - Hazuda HP
FIR - Hazuda, Helen P
IR  - Montez MG
FIR - Montez, Maria G
IR  - Hattaway K
FIR - Hattaway, Kathy
IR  - Lorenzo C
FIR - Lorenzo, Carlos
IR  - Martinez A
FIR - Martinez, Arlene
IR  - Walker T
FIR - Walker, Tatiana
IR  - Hamman RF
FIR - Hamman, Richard F
IR  - Testaverde L
FIR - Testaverde, Lisa
IR  - Anderson D
FIR - Anderson, Denise
IR  - Bouffard A
FIR - Bouffard, Alexis
IR  - Jenkins T
FIR - Jenkins, Tonya
IR  - Lenz D
FIR - Lenz, Dione
IR  - Perreault L
FIR - Perreault, Leigh
IR  - Price DW
FIR - Price, David W
IR  - Steinke SC
FIR - Steinke, Sheila C
IR  - Horton ES
FIR - Horton, Edward S
IR  - Poirier CS
FIR - Poirier, Catherine S
IR  - Swift K
FIR - Swift, Kati
IR  - Caballero E
FIR - Caballero, Enrique
IR  - Fargnoli B
FIR - Fargnoli, Barbara
IR  - Guidi A
FIR - Guidi, Ashley
IR  - Guido M
FIR - Guido, Mathew
IR  - Jackson SD
FIR - Jackson, Sharon D
IR  - Lambert L
FIR - Lambert, Lori
IR  - Lawton KE
FIR - Lawton, Kathleen E
IR  - Ledbury S
FIR - Ledbury, Sarah
IR  - Sansoucy J
FIR - Sansoucy, Jessica
IR  - Spellman J
FIR - Spellman, Jeanne
IR  - Montgomery BK
FIR - Montgomery, Brenda K
IR  - Fujimoto W
FIR - Fujimoto, Wilfred
IR  - Knopp RH
FIR - Knopp, Robert H
IR  - Lipkin EW
FIR - Lipkin, Edward W
IR  - Morgan-Taggart I
FIR - Morgan-Taggart, Ivy
IR  - Murillo A
FIR - Murillo, Anne
IR  - Taylor L
FIR - Taylor, Lonnese
IR  - Thomas A
FIR - Thomas, April
IR  - Tsai EC
FIR - Tsai, Elaine C
IR  - Trence D
FIR - Trence, Dace
IR  - Kitabchi AE
FIR - Kitabchi, Abbas E
IR  - Dagogo-Jack S
FIR - Dagogo-Jack, Samuel
IR  - Murphy ME
FIR - Murphy, Mary E
IR  - Taylor L
FIR - Taylor, Laura
IR  - Dolgoff J
FIR - Dolgoff, Jennifer
IR  - Clark D
FIR - Clark, Debra
IR  - Ibebuogu U
FIR - Ibebuogu, Uzoma
IR  - Lambeth H
FIR - Lambeth, Helen
IR  - Ricks H
FIR - Ricks, Harriet
IR  - Rutledge LMK
FIR - Rutledge, Lily M K
IR  - Soberman JE
FIR - Soberman, Judith E
IR  - Molitch ME
FIR - Molitch, Mark E
IR  - Metzger BE
FIR - Metzger, Boyd E
IR  - Johnson MK
FIR - Johnson, Mariana K
IR  - Giles MM
FIR - Giles, Mimi M
IR  - Larsen D
FIR - Larsen, Diane
IR  - Pen SC
FIR - Pen, Samsam C
IR  - Larkin M
FIR - Larkin, Mary
IR  - McKitrick C
FIR - McKitrick, Charles
IR  - Turgeon H
FIR - Turgeon, Heather
IR  - Anderson E
FIR - Anderson, Ellen
IR  - Bissett L
FIR - Bissett, Laurie
IR  - Bondi K
FIR - Bondi, Kristy
IR  - Cagliero E
FIR - Cagliero, Enrico
IR  - D'Anna K
FIR - D'Anna, Kali
IR  - Delahanty L
FIR - Delahanty, Linda
IR  - Florez JC
FIR - Florez, Jose C
IR  - Goldman V
FIR - Goldman, Valerie
IR  - Lou P
FIR - Lou, Peter
IR  - Poulos A
FIR - Poulos, Alexandra
IR  - Raymond E
FIR - Raymond, Elyse
IR  - Stevens C
FIR - Stevens, Christine
IR  - Tsent B
FIR - Tsent, Beverly
IR  - Barrett-Connor E
FIR - Barrett-Connor, Elizabeth
IR  - Carrion-Petersen ML
FIR - Carrion-Petersen, Mary Lou
IR  - Claravall LN
FIR - Claravall, Lauren N
IR  - Dowden JM
FIR - Dowden, Jonalle M
IR  - Horne J
FIR - Horne, Javiva
IR  - Leos D
FIR - Leos, Diana
IR  - Mudaliar S
FIR - Mudaliar, Sundar
IR  - Smith J
FIR - Smith, Jean
IR  - Szerdi Janisch S
FIR - Szerdi Janisch, Simona
IR  - Vejvoda K
FIR - Vejvoda, Karen
IR  - Pi-Sunyer FX
FIR - Pi-Sunyer, F Xavier
IR  - Lee JE
FIR - Lee, Jane E
IR  - Foo ST
FIR - Foo, Sandra T
IR  - Hagamen S
FIR - Hagamen, Susan
IR  - Marrero DG
FIR - Marrero, David G
IR  - Kelly SM
FIR - Kelly, Susie M
IR  - Putenney P
FIR - Putenney, Paula
IR  - Jackson MA
FIR - Jackson, Marcia A
IR  - McAtee G
FIR - McAtee, Gina
IR  - Ackermann RT
FIR - Ackermann, Ronald T
IR  - Cantrell CM
FIR - Cantrell, Carolyn M
IR  - Fineberg ES
FIR - Fineberg, Edwin S
IR  - Hadden A
FIR - Hadden, Angela
IR  - Kirkman MS
FIR - Kirkman, Mario S
IR  - O'Kelly Phillips E
FIR - O'Kelly Phillips, Erin
IR  - Roach PJ
FIR - Roach, Paris J
IR  - Ratner RE
FIR - Ratner, Robert E
IR  - Aroda V
FIR - Aroda, Vanita
IR  - Shapiro S
FIR - Shapiro, Sue
IR  - Bavido-Arrage C
FIR - Bavido-Arrage, Catherine
IR  - Gibbs P
FIR - Gibbs, Peggy
IR  - Uwaifo G
FIR - Uwaifo, Gabriel
IR  - Wiggins R
FIR - Wiggins, Renee
IR  - Saad MF
FIR - Saad, Mohammed F
IR  - Watson K
FIR - Watson, Karol
IR  - Botrous M
FIR - Botrous, Medhat
IR  - Jinagouda S
FIR - Jinagouda, Sujata
IR  - Budget M
FIR - Budget, Maria
IR  - Conzues C
FIR - Conzues, Claudia
IR  - Magpuri P
FIR - Magpuri, Perpetua
IR  - Ngo K
FIR - Ngo, Kathy
IR  - Xapthalamous K
FIR - Xapthalamous, Kathy
IR  - White NH
FIR - White, Neil H
IR  - Brown AL
FIR - Brown, Angela L
IR  - Das S
FIR - Das, Samia
IR  - Khare-Ranade P
FIR - Khare-Ranade, Prajakta
IR  - Stich T
FIR - Stich, Tamara
IR  - Santiago A
FIR - Santiago, Ana
IR  - Wernimont C
FIR - Wernimont, Cormarie
IR  - Saudek CD
FIR - Saudek, Christopher D
IR  - Hill Golden S
FIR - Hill Golden, Sherita
IR  - Whittington T
FIR - Whittington, Tracy
IR  - Brancati FL
FIR - Brancati, Frederick L
IR  - Clark JM
FIR - Clark, Jeanne M
IR  - Greene A
FIR - Greene, Alicia
IR  - Jiggetts D
FIR - Jiggetts, Dawn
IR  - Mosley H
FIR - Mosley, Henry
IR  - Reusing J
FIR - Reusing, John
IR  - Rubin RR
FIR - Rubin, Richard R
IR  - Stephens S
FIR - Stephens, Shawne
IR  - Utsey E
FIR - Utsey, Evonne
IR  - Shade DS
FIR - Shade, David S
IR  - Adams KS
FIR - Adams, Karwyn S
IR  - Hemphill C
FIR - Hemphill, Claire
IR  - Hyde P
FIR - Hyde, Penny
IR  - Canady JL
FIR - Canady, Janene L
IR  - Colleran K
FIR - Colleran, Kathleen
IR  - Gonzeles Y
FIR - Gonzeles, Ysela
IR  - Hernandez-McGinnis DA
FIR - Hernandez-McGinnis, Doris A
IR  - King C
FIR - King, Carolyn
IR  - Crandall J
FIR - Crandall, Jill
IR  - Brown JO
FIR - Brown, Janet O
IR  - Adorno E
FIR - Adorno, Elsie
IR  - Duffy H
FIR - Duffy, Helena
IR  - Goldstein A
FIR - Goldstein, Angela
IR  - Lukin J
FIR - Lukin, Jennifer
IR  - Martinez H
FIR - Martinez, Helen
IR  - Pompi D
FIR - Pompi, Dorothy
IR  - Shamoon H
FIR - Shamoon, Harry
IR  - Scheindlin J
FIR - Scheindlin, Jonathan
IR  - Wylie-Rosett J
FIR - Wylie-Rosett, Judith
IR  - Orchard T
FIR - Orchard, Trevor
IR  - Kriska A
FIR - Kriska, Andrea
IR  - Jeffries S
FIR - Jeffries, Susan
IR  - Kramer MK
FIR - Kramer, M Kaye
IR  - Smith M
FIR - Smith, Marie
IR  - Benchoff C
FIR - Benchoff, Catherine
IR  - Guimond S
FIR - Guimond, Stephanie
IR  - Pettigrew J
FIR - Pettigrew, Jessica
IR  - Rubinstein D
FIR - Rubinstein, Debra
IR  - Semler L
FIR - Semler, Linda
IR  - Venditti E
FIR - Venditti, Elizabeth
IR  - Weinzierl V
FIR - Weinzierl, Valarie
IR  - Arakaki RF
FIR - Arakaki, Richard F
IR  - Baker-Ladao NK
FIR - Baker-Ladao, Narleen K
IR  - Isonaga MK
FIR - Isonaga, Mae K
IR  - Bermudez NE
FIR - Bermudez, Nina E
IR  - Mau MK
FIR - Mau, Marjorie K
IR  - Melish JS
FIR - Melish, John S
IR  - Yamamoto RE
FIR - Yamamoto, Robin E
IR  - Cooeyate N
FIR - Cooeyate, Norman
IR  - Enote A
FIR - Enote, Alvera
IR  - Hoskin MA
FIR - Hoskin, Mary A
IR  - Natewa C
FIR - Natewa, Camille
IR  - Percy CA
FIR - Percy, Carol A
IR  - Acton KJ
FIR - Acton, Kelly J
IR  - Andre VL
FIR - Andre, Vickie L
IR  - Barber R
FIR - Barber, Roz
IR  - Begay S
FIR - Begay, Shandiin
IR  - Bucca BC
FIR - Bucca, Brian C
IR  - Cook S
FIR - Cook, Sherron
IR  - Curtis J
FIR - Curtis, Jeff
IR  - Dodge C
FIR - Dodge, Charlotte
IR  - Doughty MS
FIR - Doughty, Matthew S
IR  - Kurland J
FIR - Kurland, Jason
IR  - Glass J
FIR - Glass, Justin
IR  - Glass M
FIR - Glass, Martia
IR  - Hanson RL
FIR - Hanson, Roberta L
IR  - Ingraham LE
FIR - Ingraham, Louise E
IR  - Kobus KM
FIR - Kobus, Kathleen M
IR  - Krakoff J
FIR - Krakoff, Jonathan
IR  - Manus C
FIR - Manus, Catherine
IR  - McCabe C
FIR - McCabe, Cherie
IR  - Michaels S
FIR - Michaels, Sara
IR  - Morgan T
FIR - Morgan, Tina
IR  - Nelson JA
FIR - Nelson, Julie A
IR  - Piromalli C
FIR - Piromalli, Christopher
IR  - Roy RJ
FIR - Roy, Robert J
IR  - Sangster S
FIR - Sangster, Sandra
IR  - Smart M
FIR - Smart, Miranda
IR  - Tonemah DP
FIR - Tonemah, Darryl P
IR  - Williams R
FIR - Williams, Rachel
IR  - Wilson C
FIR - Wilson, Charlton
IR  - Fowler S
FIR - Fowler, Sarah
IR  - Larsen M
FIR - Larsen, Michael
IR  - Brenneman T
FIR - Brenneman, Tina
IR  - Sherif H
FIR - Sherif, Hanna
IR  - Abebe S
FIR - Abebe, Solome
IR  - Bamdad J
FIR - Bamdad, Julie
IR  - Barkalow M
FIR - Barkalow, Melanie
IR  - Bethepu J
FIR - Bethepu, Joel
IR  - Bezebeh T
FIR - Bezebeh, Tsedenia
IR  - Butler N
FIR - Butler, Nicole
IR  - Callaghan J
FIR - Callaghan, Jackie
IR  - Carter CE
FIR - Carter, Caitlin E
IR  - Christophi C
FIR - Christophi, Costas
IR  - Dwyer GM
FIR - Dwyer, Gregory M
IR  - Foulkes M
FIR - Foulkes, Mary
IR  - Gao Y
FIR - Gao, Yuping
IR  - Gooding R
FIR - Gooding, Robert
IR  - Gottlieb A
FIR - Gottlieb, Adrienne
IR  - Grover N
FIR - Grover, Nisha
IR  - Hoffman H
FIR - Hoffman, Heather
IR  - Hogan AN
FIR - Hogan, Ashley N
IR  - Jablonski K
FIR - Jablonski, Kathleen
IR  - Katz R
FIR - Katz, Richard
IR  - Kolinjivadi P
FIR - Kolinjivadi, Preethy
IR  - Lachin JM
FIR - Lachin, John M
IR  - Ma Y
FIR - Ma, Yong
IR  - Pan Q
FIR - Pan, Qing
IR  - Reamer S
FIR - Reamer, Susan
IR  - Sapozhnikova A
FIR - Sapozhnikova, Alla
IR  - Venditti EM
FIR - Venditti, Elizabeth M
IR  - Kriska AM
FIR - Kriska, Andrea M
IR  - Semler L
FIR - Semler, Linda
IR  - Weinzierl V
FIR - Weinzierl, Valerie
IR  - Marcovina S
FIR - Marcovina, Santica
IR  - Strylewicz G
FIR - Strylewicz, Greg
IR  - Albers J
FIR - Albers, John
IR  - Fradkin J
FIR - Fradkin, Judith
IR  - Garfield S
FIR - Garfield, Stanford
IR  - Lee C
FIR - Lee, Christine
IR  - Gregg E
FIR - Gregg, Edward
IR  - Zhang P
FIR - Zhang, Ping
IR  - Herman WH
FIR - Herman, William H
IR  - Brandle M
FIR - Brandle, Michael
IR  - Brown MB
FIR - Brown, Morton B
EDAT- 2019/03/17 06:00
MHDA- 2019/03/17 06:00
CRDT- 2019/03/17 06:00
PMCR- 2020/04/01 00:00
PHST- 2018/09/18 00:00 [received]
PHST- 2018/11/12 00:00 [accepted]
PHST- 2020/04/01 00:00 [pmc-release]
PHST- 2019/03/17 06:00 [pubmed]
PHST- 2019/03/17 06:00 [medline]
PHST- 2019/03/17 06:00 [entrez]
AID - dc18-1970 [pii]
AID - 10.2337/dc18-1970 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Apr;42(4):601-608. doi: 10.2337/dc18-1970.

PMID- 30877089
OWN - NLM
STAT- In-Data-Review
LR  - 20190321
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 42
IP  - 4
DP  - 2019 Apr
TI  - Early Detection of Hypoglycemia in Type 1 Diabetes Using Heart Rate Variability
      Measured by a Wearable Device.
PG  - 689-692
LID - 10.2337/dc18-1843 [doi]
AB  - OBJECTIVE: Changes in heart rate variability (HRV) occur at the initiation of
      hypoglycemia due to sympathetic nervous system activity. We investigated the use 
      of HRV detection by a wearable device as an early alert for hypoglycemia.
      RESEARCH DESIGN AND METHODS: This proof-of-principle study included 23 patients
      with type 1 diabetes (14 women, mean age 42 +/- 11 years). Patients wore a
      VitalConnect HealthPatch for 5 days. Hypoglycemia was defined as glucose </=70
      mg/dL (</=3.9 mmol/L) by fingerstick measurement. HRV was analyzed in
      standardized periods before the hypoglycemic event. RESULTS: Sixty-six
      hypoglycemic events were recorded. Hypoglycemia caused a typical HRV pattern in
      36 (55%) of the hypoglycemic events. Eighteen events (27%) showed an atypical
      pattern. Ten events were unclassified (15%), and two did not display a change in 
      HRV (3%). CONCLUSIONS: Hypoglycemia causes early changes in HRV that can be
      detected by a wearable device. Measuring real-time HRV seems promising for early 
      hypoglycemia detection.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Olde Bekkink, Marleen
AU  - Olde Bekkink M
AUID- ORCID: http://orcid.org/0000-0002-2619-3897
AD  - Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the
      Netherlands marleen.oldebekkink@radboudumc.nl.
FAU - Koeneman, Mats
AU  - Koeneman M
AD  - REshape Center for Innovation, Radboud University Medical Center, Nijmegen, the
      Netherlands.
FAU - de Galan, Bastiaan E
AU  - de Galan BE
AD  - Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the
      Netherlands.
FAU - Bredie, Sebastian J
AU  - Bredie SJ
AD  - Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the
      Netherlands.
AD  - REshape Center for Innovation, Radboud University Medical Center, Nijmegen, the
      Netherlands.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/03/17 06:00
MHDA- 2019/03/17 06:00
CRDT- 2019/03/17 06:00
PHST- 2018/08/31 00:00 [received]
PHST- 2019/01/10 00:00 [accepted]
PHST- 2019/03/17 06:00 [pubmed]
PHST- 2019/03/17 06:00 [medline]
PHST- 2019/03/17 06:00 [entrez]
AID - dc18-1843 [pii]
AID - 10.2337/dc18-1843 [doi]
PST - ppublish
SO  - Diabetes Care. 2019 Apr;42(4):689-692. doi: 10.2337/dc18-1843.

PMID- 30862659
OWN - NLM
STAT- Publisher
LR  - 20190313
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2019 Mar 12
TI  - Comparative Effectiveness and Maintenance of Diabetes Self-Management Education
      Interventions for Marshallese Patients With Type 2 Diabetes: A Randomized
      Controlled Trial.
LID - dc181985 [pii]
LID - 10.2337/dc18-1985 [doi]
AB  - OBJECTIVE: Marshallese adults experience high rates of type 2 diabetes. Previous 
      diabetes self-management education (DSME) interventions among Marshallese were
      unsuccessful. This study compared the extent to which two DSME interventions
      improved glycemic control, measured on the basis of change in glycated hemoglobin
      (HbA1c). RESEARCH DESIGN AND METHODS: A two-arm randomized controlled trial
      compared a standard-model DSME (standard DSME) with a culturally adapted
      family-model DSME (adapted DSME). Marshallese adults with type 2 diabetes (n =
      221) received either standard DSME in a community setting (n = 111) or adapted
      DSME in a home setting (n = 110). Outcome measures were assessed at baseline,
      immediately after the intervention, and at 6 and 12 months after the
      intervention, and were examined with adjusted linear mixed-effects regression
      models. RESULTS: Participants in the adapted DSME arm showed significantly
      greater declines in mean HbA1c immediately (-0.61% [95% CI -1.19, -0.03]; P =
      0.038) and 12 months (-0.77% [95% CI -1.38, -0.17]; P = 0.013) after the
      intervention than those in the standard DSME arm. Within the adapted DSME arm,
      participants had significant reductions in mean HbA1c from baseline to
      immediately after the intervention (-1.18% [95% CI -1.55, -0.81]), to 6 months
      (-0.67% [95% CI -1.06, -0.28]), and to 12 months (-0.87% [95% CI -1.28, -0.46])
      (P < 0.001 for all). Participants in the standard DSME arm had significant
      reductions in mean HbA1c from baseline to immediately after the intervention
      (-0.55% [95% CI -0.93, -0.17]; P = 0.005). CONCLUSIONS: Participants receiving
      the adapted DSME showed significantly greater reductions in mean HbA1c
      immediately after and 12 months after the intervention than the reductions among 
      those receiving standard DSME. This study adds to the body of research that shows
      the potential effectiveness of culturally adapted DSME that includes
      participants' family members.
CI  - (c) 2019 by the American Diabetes Association.
FAU - McElfish, Pearl A
AU  - McElfish PA
AUID- ORCID: http://orcid.org/0000-0002-4033-6241
AD  - College of Medicine, University of Arkansas for Medical Sciences Northwest,
      Fayetteville, AR pamcelfish@uams.edu.
FAU - Long, Christopher R
AU  - Long CR
AD  - College of Medicine, University of Arkansas for Medical Sciences Northwest,
      Fayetteville, AR.
FAU - Kohler, Peter O
AU  - Kohler PO
AD  - College of Medicine, University of Arkansas for Medical Sciences Northwest,
      Fayetteville, AR.
FAU - Yeary, Karen H K
AU  - Yeary KHK
AD  - Fay W. Boozman College of Public Health, University of Arkansas for Medical
      Sciences, Little Rock, AR.
FAU - Bursac, Zoran
AU  - Bursac Z
AD  - Department of Biostatistics, Robert Stempel College of Public Health and Social
      Work, Florida International University, Miami, FL.
FAU - Narcisse, Marie-Rachelle
AU  - Narcisse MR
AD  - College of Medicine, University of Arkansas for Medical Sciences Northwest,
      Fayetteville, AR.
FAU - Felix, Holly C
AU  - Felix HC
AD  - Fay W. Boozman College of Public Health, University of Arkansas for Medical
      Sciences, Little Rock, AR.
FAU - Rowland, Brett
AU  - Rowland B
AD  - Office of Community Health and Research, University of Arkansas for Medical
      Sciences Northwest, Fayetteville, AR.
FAU - Hudson, Jonell S
AU  - Hudson JS
AD  - College of Pharmacy, University of Arkansas for Medical Sciences Northwest,
      Fayetteville, AR.
FAU - Goulden, Peter A
AU  - Goulden PA
AD  - College of Medicine, University of Arkansas for Medical Sciences, Little Rock,
      AR.
LA  - eng
PT  - Journal Article
DEP - 20190312
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/03/14 06:00
MHDA- 2019/03/14 06:00
CRDT- 2019/03/14 06:00
PHST- 2018/09/19 00:00 [received]
PHST- 2019/02/07 00:00 [accepted]
PHST- 2019/03/14 06:00 [entrez]
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2019/03/14 06:00 [medline]
AID - dc18-1985 [pii]
AID - 10.2337/dc18-1985 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2019 Mar 12. pii: dc18-1985. doi: 10.2337/dc18-1985.

PMID- 30862658
OWN - NLM
STAT- Publisher
LR  - 20190313
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2019 Mar 12
TI  - Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With
      Posttransplant Diabetes Mellitus.
LID - dc190093 [pii]
LID - 10.2337/dc19-0093 [doi]
AB  - OBJECTIVE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have lately become
      the recommended treatment in patients with type 2 diabetes and high
      cardiovascular risk. Patients with posttransplant diabetes mellitus (PTDM) also
      have high cardiovascular risk. The aim of this study was to investigate the
      safety and efficacy of empagliflozin in renal transplant recipients with PTDM.
      RESEARCH DESIGN AND METHODS: Forty-nine renal transplant recipients were included
      in an investigator-initiated, single-center, prospective, double-blind study and 
      randomized to receive either 10 mg empagliflozin or placebo once daily for 24
      weeks. Patients transplanted >1 year ago, diagnosed with PTDM, with stable renal 
      function (estimated glomerular filtration rate [eGFR] >30 mL/min/1.73 m(2)), and 
      with stable immunosuppressive therapy were studied. RESULTS: Forty-four renal
      transplant recipients (22 empagliflozin/22 placebo, 34 males) completed the
      study. Median (interquartile range) change in glycated hemoglobin (HbA1c) was
      significantly reduced with empagliflozin compared with placebo: -0.2% (-0.6,
      -0.1) (-2.0 mmol/mol [-6.5, -1.0]) vs. 0.1% (-0.1, 0.4) (1.0 mmol/mol [-0.75,
      3.8]) (P = 0.025). The magnitude of glucose reduction was dependent on GFR and
      baseline HbA1c. The treatment also resulted in a significant reduction in body
      weight of -2.5 kg (-4.0, -0.05) compared with an increase of 1.0 kg (0.0, 2.0) in
      the placebo group (P = 0.014). There were no significant differences between the 
      groups in adverse events, immunosuppressive drug levels, or eGFR. CONCLUSIONS:
      Empagliflozin appeared safe and improved glycemic control in renal transplant
      recipients with PTDM compared with placebo. A concomitant reduction in body
      weight was seen.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Halden, Thea Anine Strom
AU  - Halden TAS
AD  - Department of Transplantation Medicine, Section of Nephrology, Oslo University
      Hospital, Rikshospitalet, Oslo, Norway.
FAU - Kvitne, Kine Eide
AU  - Kvitne KE
AUID- ORCID: http://orcid.org/0000-0001-8118-7660
AD  - Section of Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy,
      University of Oslo, Oslo, Norway k.e.kvitne@farmasi.uio.no.
FAU - Midtvedt, Karsten
AU  - Midtvedt K
AD  - Department of Transplantation Medicine, Section of Nephrology, Oslo University
      Hospital, Rikshospitalet, Oslo, Norway.
FAU - Rajakumar, Laavanyaah
AU  - Rajakumar L
AD  - Department of Transplantation Medicine, Section of Nephrology, Oslo University
      Hospital, Rikshospitalet, Oslo, Norway.
FAU - Robertsen, Ida
AU  - Robertsen I
AD  - Section of Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy,
      University of Oslo, Oslo, Norway.
FAU - Brox, Jan
AU  - Brox J
AD  - Department of Laboratory Medicine, University Hospital of North Norway, Tromso,
      Norway.
FAU - Bollerslev, Jens
AU  - Bollerslev J
AD  - Faculty of Medicine, University of Oslo, Oslo, Norway.
AD  - Section of Specialized Endocrinology, Department of Endocrinology, Oslo
      University Hospital, Rikshospitalet, Oslo, Norway.
FAU - Hartmann, Anders
AU  - Hartmann A
AD  - Department of Transplantation Medicine, Section of Nephrology, Oslo University
      Hospital, Rikshospitalet, Oslo, Norway.
FAU - Asberg, Anders
AU  - Asberg A
AD  - Department of Transplantation Medicine, Section of Nephrology, Oslo University
      Hospital, Rikshospitalet, Oslo, Norway.
AD  - Section of Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy,
      University of Oslo, Oslo, Norway.
FAU - Jenssen, Trond
AU  - Jenssen T
AD  - Department of Transplantation Medicine, Section of Nephrology, Oslo University
      Hospital, Rikshospitalet, Oslo, Norway.
AD  - Faculty of Medicine, University of Oslo, Oslo, Norway.
LA  - eng
PT  - Journal Article
DEP - 20190312
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/03/14 06:00
MHDA- 2019/03/14 06:00
CRDT- 2019/03/14 06:00
PHST- 2019/01/14 00:00 [received]
PHST- 2019/02/15 00:00 [accepted]
PHST- 2019/03/14 06:00 [entrez]
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2019/03/14 06:00 [medline]
AID - dc19-0093 [pii]
AID - 10.2337/dc19-0093 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2019 Mar 12. pii: dc19-0093. doi: 10.2337/dc19-0093.

PMID- 30862657
OWN - NLM
STAT- Publisher
LR  - 20190313
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2019 Mar 12
TI  - Risk of Incident Obstructive Sleep Apnea Among Patients With Type 2 Diabetes.
LID - dc182004 [pii]
LID - 10.2337/dc18-2004 [doi]
AB  - OBJECTIVE: This study compared the incidence of obstructive sleep apnea (OSA) in 
      patients with and without type 2 diabetes and investigated risk factors for OSA
      in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A retrospective
      cohort study was performed to compare OSA incidence between adult patients with
      and without type 2 diabetes matched for age, sex, and BMI. Patients with a
      prevalent OSA diagnosis were excluded. The study cohort was derived from The
      Health Improvement Network (THIN), a U.K. primary care database, from 1 January
      2005 to 31 December 2017. RESULTS: There were 3,110 (0.88%) and 5,968 (0.46%)
      incident OSA cases identified in the 360,250 exposed and 1,296,489 unexposed
      patient cohorts, respectively. Adjusted incidence rate ratio (aIRR) of OSA in
      patients with type 2 diabetes compared with those without was 1.48 (95% CI
      1.42-1.55; P < 0.001). In a multivariate regression analysis of patients with
      type 2 diabetes, significant predictors of OSA were diabetes-related foot disease
      (1.23 [1.06-1.42]; P = 0.005), being prescribed insulin in the last 60 days (1.58
      [1.42-1.75]; P < 0.001), male sex (2.27 [2.09-2.46]; P < 0.001), being overweight
      (2.02 [1.54-2.64]; P < 0.001) or obese (8.29 [6.42-10.69]; P < 0.001), heart
      failure (1.41 [1.18-1.70]; P < 0.001), ischemic heart disease (1.22 [1.11-1.34]; 
      P < 0.001), atrial fibrillation (1.23 [1.04-1.46]; P = 0.015), hypertension (1.32
      [1.23-1.43]; P < 0.001), and depression (1.75 [1.61-1.91]; P < 0.001).
      CONCLUSIONS: When considered alongside previous evidence, this study indicates
      that the association between type 2 diabetes and OSA is bidirectional. In
      addition to known predictors of OSA, diabetes-related foot disease and insulin
      treatment were identified as risk factors in patients with type 2 diabetes.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Subramanian, Anuradhaa
AU  - Subramanian A
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, U.K.
FAU - Adderley, Nicola J
AU  - Adderley NJ
AUID- ORCID: http://orcid.org/0000-0003-0543-3254
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, U.K.
FAU - Tracy, Alexander
AU  - Tracy A
AD  - Institute of Clinical Sciences, Centre for Translational Inflammation Research,
      University of Birmingham, Birmingham, U.K.
FAU - Taverner, Tom
AU  - Taverner T
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, U.K.
FAU - Hanif, Wasim
AU  - Hanif W
AD  - University Hospital Birmingham, Birmingham, U.K.
FAU - Toulis, Konstantinos A
AU  - Toulis KA
AUID- ORCID: http://orcid.org/0000-0002-2044-4253
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, U.K.
FAU - Thomas, G Neil
AU  - Thomas GN
AUID- ORCID: http://orcid.org/0000-0002-2777-1847
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, U.K. 
      gneilthomas@yahoo.co.uk g.n.thomas@bham.ac.uk.
FAU - Tahrani, Abd A
AU  - Tahrani AA
AD  - Institute of Metabolism and Systems Research, University of Birmingham,
      Birmingham, U.K.
AD  - Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners,
      Birmingham, U.K.
FAU - Nirantharakumar, Krishnarajah
AU  - Nirantharakumar K
AUID- ORCID: http://orcid.org/0000-0002-6816-1279
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, U.K.
AD  - Institute of Metabolism and Systems Research, University of Birmingham,
      Birmingham, U.K.
AD  - Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners,
      Birmingham, U.K.
AD  - Midlands Health Data Research, U.K.
LA  - eng
PT  - Journal Article
DEP - 20190312
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/03/14 06:00
MHDA- 2019/03/14 06:00
CRDT- 2019/03/14 06:00
PHST- 2018/09/21 00:00 [received]
PHST- 2019/01/27 00:00 [accepted]
PHST- 2019/03/14 06:00 [entrez]
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2019/03/14 06:00 [medline]
AID - dc18-2004 [pii]
AID - 10.2337/dc18-2004 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2019 Mar 12. pii: dc18-2004. doi: 10.2337/dc18-2004.

PMID- 30862656
OWN - NLM
STAT- Publisher
LR  - 20190313
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2019 Mar 12
TI  - Disordered Eating Behaviors in Youth and Young Adults With Type 1 or Type 2
      Diabetes Receiving Insulin Therapy: The SEARCH for Diabetes in Youth Study.
LID - dc182420 [pii]
LID - 10.2337/dc18-2420 [doi]
AB  - OBJECTIVE: This study examines the prevalence of disordered eating behaviors
      (DEB) and its associations with glycemic control, insulin sensitivity (IS), and
      psychosocial functioning in a large, diverse cohort of youth and young adults
      with type 1 or type 2 diabetes. RESEARCH DESIGN AND METHODS: In the SEARCH for
      Diabetes in Youth study, 2,156 youth and young adults with type 1 diabetes (mean 
      +/- SD age 17.7 +/- 4.3 years; 50.0% female) and 149 youth and young adults with 
      type 2 diabetes (age 21.8 years +/- 3.5; 64.4% female) who were receiving insulin
      therapy completed the Diabetes Eating Problem Survey-Revised (DEPS-R), a
      self-reported measure for identifying disordered eating. DEB was defined as a
      DEPS-R score >/=20. Demographic characteristics, clinical measures, and health
      behaviors of participants with DEB and those without DEB were compared by using t
      tests. RESULTS: DEB were observed in 21.2% of participants with type 1 diabetes
      and 50.3% of participants with type 2 diabetes. Participants encountered
      challenges in maintaining a healthy weight while controlling their diabetes. For 
      both types of diabetes, individuals with DEB had a significantly higher BMI z
      score, lower insulin sensitivity, more depressive symptoms, and poorer quality of
      life than those without DEB. Diabetic ketoacidosis (DKA) episodes occurred more
      frequently in youth with type 1 diabetes with DEB compared to those without DEB. 
      CONCLUSIONS: These findings highlight that DEB are prevalent among youth and
      young adults with type 1 and type 2 diabetes and who are receiving insulin
      therapy, and DEB are associated with poorer clinical outcomes and psychosocial
      well-being. Heightened awareness and early interventions are needed to address
      DEB for this at-risk population, as are longitudinal studies evaluating the
      course of DEB and diabetes outcomes.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Nip, Angel S Y
AU  - Nip ASY
FAU - Reboussin, Beth A
AU  - Reboussin BA
FAU - Dabelea, Dana
AU  - Dabelea D
AUID- ORCID: http://orcid.org/0000-0001-9514-8929
FAU - Bellatorre, Anna
AU  - Bellatorre A
AUID- ORCID: http://orcid.org/0000-0002-5414-0741
FAU - Mayer-Davis, Elizabeth J
AU  - Mayer-Davis EJ
AUID- ORCID: http://orcid.org/0000-0003-3858-0517
FAU - Kahkoska, Anna R
AU  - Kahkoska AR
AUID- ORCID: http://orcid.org/0000-0003-2701-101X
FAU - Lawrence, Jean M
AU  - Lawrence JM
FAU - Peterson, Claire M
AU  - Peterson CM
FAU - Dolan, Lawrence
AU  - Dolan L
FAU - Pihoker, Catherine
AU  - Pihoker C
AUID- ORCID: http://orcid.org/0000-0001-9074-7770
CN  - SEARCH for Diabetes in Youth Study Group
LA  - eng
PT  - Journal Article
DEP - 20190312
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
IR  - Lawrence JM
FIR - Lawrence, Jean M
IR  - Koebnick C
FIR - Koebnick, Corinna
IR  - Reynolds K
FIR - Reynolds, Kristi
IR  - Li X
FIR - Li, Xia
IR  - Hung P
FIR - Hung, Peggy
IR  - Lustigova E
FIR - Lustigova, Eva
IR  - Pettitt DJ
FIR - Pettitt, David J
IR  - Dabelea D
FIR - Dabelea, Dana
IR  - Hamman RF
FIR - Hamman, Richard F
IR  - Testaverde L
FIR - Testaverde, Lisa
IR  - Bellatorre A
FIR - Bellatorre, Anna
IR  - Klingensmith GJ
FIR - Klingensmith, Georgeanna J
IR  - Rewers MJ
FIR - Rewers, Marian J
IR  - Maahs D
FIR - Maahs, David
IR  - Wadwa P
FIR - Wadwa, Paul
IR  - Daniels S
FIR - Daniels, Stephen
IR  - Wilkening G
FIR - Wilkening, Greta
IR  - Kahn MG
FIR - Kahn, Michael G
IR  - Bloch CA
FIR - Bloch, Clifford A
IR  - Powell J
FIR - Powell, Jeffrey
IR  - Love-Osborne K
FIR - Love-Osborne, Kathy
IR  - Hu DC
FIR - Hu, Diana C
IR  - Dolan LM
FIR - Dolan, Lawrence M
IR  - Shah AS
FIR - Shah, Amy S
IR  - Urbina EM
FIR - Urbina, Elaine M
IR  - Standiford DA
FIR - Standiford, Debra A
IR  - Mayer-Davis EJ
FIR - Mayer-Davis, Elizabeth J
IR  - Mottl A
FIR - Mottl, Amy
IR  - Thomas J
FIR - Thomas, Joan
IR  - Liese AD
FIR - Liese, Angela D
IR  - Jackson M
FIR - Jackson, Malaka
IR  - Knight L
FIR - Knight, Lisa
IR  - Bowlby D
FIR - Bowlby, Deborah
IR  - Amrhein J
FIR - Amrhein, James
IR  - Nelson B
FIR - Nelson, Bryce
IR  - Apperson E
FIR - Apperson, Elaine
IR  - Pihoker C
FIR - Pihoker, Catherine
IR  - Hirsch I
FIR - Hirsch, Irl
IR  - Liu LL
FIR - Liu, Lenna L
IR  - Afkarian M
FIR - Afkarian, Maryam
IR  - Kim G
FIR - Kim, Grace
IR  - Taplin C
FIR - Taplin, Craig
IR  - Malik F
FIR - Malik, Faisal
IR  - Nip A
FIR - Nip, Angel
IR  - Yi-Frazier J
FIR - Yi-Frazier, Joyce
IR  - Merjaneh L
FIR - Merjaneh, Lina
IR  - Wright D
FIR - Wright, Davene
IR  - Roberts A
FIR - Roberts, Alissa
IR  - Loots B
FIR - Loots, Beth
IR  - Beauregard N
FIR - Beauregard, Natalie
IR  - Kearns S
FIR - Kearns, Sue
IR  - Klingsheim M
FIR - Klingsheim, Mary
IR  - Pascual M
FIR - Pascual, Michael
IR  - Franklin C
FIR - Franklin, Cordelia
IR  - Gangan C
FIR - Gangan, Carlo
IR  - Greenbaum C
FIR - Greenbaum, Carla
IR  - Imperatore G
FIR - Imperatore, Giuseppina
IR  - Saydah SH
FIR - Saydah, Sharon H
IR  - Linder B
FIR - Linder, Barbara
IR  - Marcovina SM
FIR - Marcovina, Santica M
IR  - Clouet N
FIR - Clouet, Noemie
IR  - Foraison G
FIR - Foraison, Greg
IR  - Strylewicz A
FIR - Strylewicz, Alan
IR  - Chait J
FIR - Chait, Jessica
IR  - Harting R
FIR - Harting, Ralph
IR  - D'Agostino LE
FIR - D'Agostino, Lynne E
IR  - Wagenknecht J
FIR - Wagenknecht, Jasmin
IR  - Divers B
FIR - Divers, Beth
IR  - Reboussin ET
FIR - Reboussin, Elizabeth T
IR  - Jensen B
FIR - Jensen, Brian
IR  - Wells R
FIR - Wells, Ramon
IR  - Casanova L
FIR - Casanova, Leora
IR  - Henkin K
FIR - Henkin, Kristin
IR  - Lenoir MT
FIR - Lenoir, Maureen T
IR  - Goldstein C
FIR - Goldstein, Carrie
IR  - Williams S
FIR - Williams, Scott
IR  - Isom J
FIR - Isom, Jeanette
IR  - Stafford C
FIR - Stafford, Cynthia
IR  - Suerken
FIR - Suerken
IR  - Pierce J
FIR - Pierce, June
EDAT- 2019/03/14 06:00
MHDA- 2019/03/14 06:00
CRDT- 2019/03/14 06:00
PHST- 2018/11/24 00:00 [received]
PHST- 2019/02/21 00:00 [accepted]
PHST- 2019/03/14 06:00 [entrez]
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2019/03/14 06:00 [medline]
AID - dc18-2420 [pii]
AID - 10.2337/dc18-2420 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2019 Mar 12. pii: dc18-2420. doi: 10.2337/dc18-2420.

PMID- 30862655
OWN - NLM
STAT- Publisher
LR  - 20190319
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2019 Mar 12
TI  - Intractable Coronary Artery Disease in a Patient with Type 2 Diabetes Presenting 
      With Triglyceride Deposit Cardiomyovasculopathy.
LID - dc182365 [pii]
LID - 10.2337/dc18-2365 [doi]
FAU - Kozawa, Junji
AU  - Kozawa J
AD  - Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 
      Osaka, Japan.
FAU - Higashi, Masahiro
AU  - Higashi M
AD  - Department of Radiology, Osaka National Hospital, National Hospital Organization,
      Osaka, Japan.
FAU - Shimomura, Iichiro
AU  - Shimomura I
AD  - Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 
      Osaka, Japan.
FAU - Hirano, Ken-Ichi
AU  - Hirano KI
AUID- ORCID: http://orcid.org/0000-0002-3535-957X
AD  - Laboratory of Cardiovascular Disease, Novel, Non-invasive, and Nutritional
      Therapeutics (CNT), Graduate School of Medicine, Osaka University, Osaka, Japan
      khirano@cnt-osaka.com.
LA  - eng
PT  - Journal Article
DEP - 20190312
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/03/14 06:00
MHDA- 2019/03/14 06:00
CRDT- 2019/03/14 06:00
PHST- 2018/11/17 00:00 [received]
PHST- 2019/01/21 00:00 [accepted]
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2019/03/14 06:00 [medline]
PHST- 2019/03/14 06:00 [entrez]
AID - dc18-2365 [pii]
AID - 10.2337/dc18-2365 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2019 Mar 12. pii: dc18-2365. doi: 10.2337/dc18-2365.

PMID- 30862654
OWN - NLM
STAT- Publisher
LR  - 20190313
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2019 Mar 12
TI  - Underuse of Medications and Lifestyle Counseling to Prevent Cardiovascular
      Disease in Patients With Diabetes.
LID - dc181554 [pii]
LID - 10.2337/dc18-1554 [doi]
FAU - Newman, Jonathan D
AU  - Newman JD
AUID- ORCID: http://orcid.org/0000-0001-6855-7305
AD  - Division of Cardiology, Department of Medicine, New York University School of
      Medicine, New York, NY jonathan.newman@nyumc.org.
FAU - Berger, Jeffrey S
AU  - Berger JS
AD  - Division of Cardiology, Department of Medicine, New York University School of
      Medicine, New York, NY.
AD  - Division of Vascular Surgery, Department of Surgery, New York University School
      of Medicine, New York, NY.
FAU - Ladapo, Joseph A
AU  - Ladapo JA
AD  - Division of General Internal Medicine and Health Services Research, Department of
      Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
LA  - eng
PT  - Letter
DEP - 20190312
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/03/14 06:00
MHDA- 2019/03/14 06:00
CRDT- 2019/03/14 06:00
PHST- 2018/07/19 00:00 [received]
PHST- 2019/02/18 00:00 [accepted]
PHST- 2019/03/14 06:00 [entrez]
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2019/03/14 06:00 [medline]
AID - dc18-1554 [pii]
AID - 10.2337/dc18-1554 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2019 Mar 12. pii: dc18-1554. doi: 10.2337/dc18-1554.

PMID- 30862653
OWN - NLM
STAT- Publisher
LR  - 20190313
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2019 Mar 12
TI  - Post-ACA Racial Disparity of Eye Examinations Among the U.S. Noninstitutionalized
      Population With Diabetes: 2014-2015.
LID - dc181991 [pii]
LID - 10.2337/dc18-1991 [doi]
FAU - Monnette, Alisha M
AU  - Monnette AM
AD  - Department of Global Health Management and Policy, Tulane University School of
      Public Health and Tropical Medicine, New Orleans, LA.
FAU - Wharton, M Kristina
AU  - Wharton MK
AD  - Department of Global Health Management and Policy, Tulane University School of
      Public Health and Tropical Medicine, New Orleans, LA.
FAU - Zhao, Yingnan
AU  - Zhao Y
AD  - Division of Clinical and Administrative Science, College of Pharmacy, Xavier
      University of Louisiana, New Orleans, LA.
FAU - Fonseca, Vivian A
AU  - Fonseca VA
AUID- ORCID: http://orcid.org/0000-0002-3381-7151
AD  - Section of Endocrinology, Department of Medicine, School of Medicine, Tulane
      University, New Orleans, LA.
FAU - Shi, Lizheng
AU  - Shi L
AUID- ORCID: http://orcid.org/0000-0002-7252-8686
AD  - Department of Global Health Management and Policy, Tulane University School of
      Public Health and Tropical Medicine, New Orleans, LA lshi1@tulane.edu.
LA  - eng
PT  - Letter
DEP - 20190312
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/03/14 06:00
MHDA- 2019/03/14 06:00
CRDT- 2019/03/14 06:00
PHST- 2018/09/20 00:00 [received]
PHST- 2019/01/21 00:00 [accepted]
PHST- 2019/03/14 06:00 [entrez]
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2019/03/14 06:00 [medline]
AID - dc18-1991 [pii]
AID - 10.2337/dc18-1991 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2019 Mar 12. pii: dc18-1991. doi: 10.2337/dc18-1991.

PMID- 30862651
OWN - NLM
STAT- Publisher
LR  - 20190319
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
DP  - 2019 Mar 12
TI  - Testosterone Therapy in Men With Hypogonadism Prevents Progression From
      Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study.
LID - dc182388 [pii]
LID - 10.2337/dc18-2388 [doi]
AB  - OBJECTIVE: Type 2 diabetes (T2D) is a public health threat. Prediabetes
      represents a window of opportunity for intervention to prevent T2D. Men with T2D 
      and prediabetes often have low testosterone. Since testosterone improves glycemic
      control in T2D, we investigated whether testosterone therapy (TTh) in men with
      hypogonadism and prediabetes prevents progression to T2D. RESEARCH DESIGN AND
      METHODS: Three hundred sixteen men with prediabetes (defined as HbA1c 5.7-6.4%)
      and total testosterone levels </=12.1 nmol/L combined with symptoms of
      hypogonadism were analyzed. Two hundred twenty-nine men received parenteral
      testosterone undecanoate (T-group), and 87 men with hypogonadism served as
      untreated control subjects. Metabolic and anthropometric parameters were measured
      twice yearly for 8 years. RESULTS: HbA1c decreased by 0.39 +/- 0.03% (P < 0.0001)
      in the T-group and increased by 0.63 +/- 0.1% (P < 0.0001) in the untreated
      group. In the T-group, 90% achieved normal glucose regulation (HbA1c <5.7%). In
      the untreated group, 40.2% progressed to T2D (HbA1c >6.5%). TTh was also
      associated with significant improvements in fasting glucose, triglyceride:HDL
      ratio, triglyceride-glucose index, lipid accumulation product, total cholesterol,
      LDL, HDL, non-HDL, triglycerides, and Aging Males' Symptoms (AMS) scale.
      Significant deterioration in all these parameters was seen in the untreated
      group. Mortality was 7.4% in the T-group and 16.1% in the untreated group (P <
      0.05). The incidence of nonfatal myocardial infarction was 0.4% in the T-group
      and 5.7% in the untreated group (P < 0.005). CONCLUSIONS: Long-term TTh
      completely prevents prediabetes progression to T2D in men with hypogonadism and
      improves glycemia, lipids, and AMS score. TTh holds tremendous potential for the 
      large and growing population of men with prediabetes and hypogonadism.
CI  - (c) 2019 by the American Diabetes Association.
FAU - Yassin, Aksam
AU  - Yassin A
AD  - Institute for Urology and Andrology, Norderstedt, Germany.
AD  - Dresden International University, Dresden, Germany.
AD  - Department of Surgery, Division of Urology/Andrology, Hamad Medical Corporation, 
      Doha, Qatar.
FAU - Haider, Ahmad
AU  - Haider A
AD  - Private Urology Practice, Bremerhaven, Germany.
FAU - Haider, Karim S
AU  - Haider KS
AD  - Private Urology Practice, Bremerhaven, Germany.
FAU - Caliber, Monica
AU  - Caliber M
AD  - American Medical Writers Association, Fort Lauderdale, FL.
FAU - Doros, Gheorghe
AU  - Doros G
AD  - Department of Epidemiology and Statistics, Boston University School of Public
      Health, Boston, MA.
FAU - Saad, Farid
AU  - Saad F
AUID- ORCID: http://orcid.org/0000-0002-0449-6635
AD  - Medical Affairs Andrology, Bayer AG, Berlin, Germany farid.saad@bayer.com.
AD  - Gulf Medical University School of Medicine, Ajman, United Arab Emirates.
FAU - Garvey, W Timothy
AU  - Garvey WT
AUID- ORCID: http://orcid.org/0000-0003-0822-0860
AD  - Department of Nutrition Sciences, University of Alabama at Birmingham and the
      Birmingham VA Medical Center, Birmingham, AL.
LA  - eng
PT  - Journal Article
DEP - 20190312
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2019/03/14 06:00
MHDA- 2019/03/14 06:00
CRDT- 2019/03/14 06:00
PHST- 2018/11/19 00:00 [received]
PHST- 2019/02/18 00:00 [accepted]
PHST- 2019/03/14 06:00 [pubmed]
PHST- 2019/03/14 06:00 [medline]
PHST- 2019/03/14 06:00 [entrez]
AID - dc18-2388 [pii]
AID - 10.2337/dc18-2388 [doi]
PST - aheadofprint
SO  - Diabetes Care. 2019 Mar 12. pii: dc18-2388. doi: 10.2337/dc18-2388.

PMID- 30869793
OWN - NLM
STAT- Publisher
LR  - 20190314
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2019 Mar 14
TI  - Potential Role of Metal Chelation to Prevent the Cardiovascular Complications of 
      Diabetes.
LID - jc.2018-01484 [pii]
LID - 10.1210/jc.2018-01484 [doi]
AB  - CONTEXT: For decades, there has been epidemiologic evidence linking chronic toxic
      metal exposure with cardiovascular disease, suggesting a therapeutic role for
      metal chelation. Given the lack of compelling scientific evidence however, the
      indications for metal chelation were never clearly defined. To determine the
      safety and efficacy of chelation therapy, the National Institutes of Health
      funded the Trial to Assess Chelation Therapy (TACT). TACT was the first double
      blind, randomized, controlled trial to demonstrate an improvement in
      cardiovascular outcomes with edetate disodium therapy in patients with prior
      myocardial infarction. The therapeutic benefit was striking among the
      pre-specified subgroup of diabetic patients. EVIDENCE ACQUISITION: We review the 
      published literature focusing on the atherogenic nature of diabetes, and
      available evidence from clinical trials, complete and in progress, of metal
      chelation with edetate disodium therapy in diabetic patients. EVIDENCE SYNTHESIS:
      The TACT results support the concept that ubiquitous toxic metals such as lead
      and cadmium may be modifiable risk factors for cardiovascular disease,
      particularly in diabetic patients. CONCLUSIONS: The purpose of this review is to 
      discuss the potential mechanisms unifying the pathogenesis of atherogenic factors
      in diabetes with toxic metal exposure, and the potential role of metal chelation.
CI  - Copyright (c) 2019 Endocrine Society.
FAU - Moreno, Rossana Calderon
AU  - Moreno RC
AD  - From the Mount Sinai Medical Center Department of Medicine, Miami Beach, FL.
FAU - Navas-Acien, Ana
AU  - Navas-Acien A
AD  - Columbia University Mailman School of Public Health, New York, New York.
FAU - Escolar, Esteban
AU  - Escolar E
AD  - Department of Medicine, Columbia University Division of Cardiology at Mount Sinai
      Medical Center, Miami Beach FL.
FAU - Nathan, David M
AU  - Nathan DM
AD  - Diabetes Unit, Massachusetts General Hospital and Harvard Medical School, Boston,
      Massachusetts.
FAU - Newman, Jonathan
AU  - Newman J
AD  - Department of Medicine, New York University School of Medicine, New York, New
      York.
FAU - Schmedtje, John F
AU  - Schmedtje JF
AD  - Roanoke Heart Institute PLC, Roanoke, Virginia.
FAU - Diaz, Denisse
AU  - Diaz D
AD  - Department of Medicine, Columbia University Division of Cardiology at Mount Sinai
      Medical Center, Miami Beach FL.
FAU - Lamas, Gervasio A
AU  - Lamas GA
AD  - Department of Medicine, Columbia University Division of Cardiology at Mount Sinai
      Medical Center, Miami Beach FL.
FAU - Fonseca, Vivian
AU  - Fonseca V
AD  - Department of Medicine, Tulane University School of Medicine, New Orleans,
      Louisiana.
LA  - eng
PT  - Journal Article
DEP - 20190314
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2019/03/15 06:00
MHDA- 2019/03/15 06:00
CRDT- 2019/03/15 06:00
PHST- 2018/07/25 00:00 [received]
PHST- 2019/03/07 00:00 [accepted]
PHST- 2019/03/15 06:00 [entrez]
PHST- 2019/03/15 06:00 [pubmed]
PHST- 2019/03/15 06:00 [medline]
AID - 5376633 [pii]
AID - 10.1210/jc.2018-01484 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2019 Mar 14. pii: 5376633. doi: 10.1210/jc.2018-01484.

PMID- 30860050
OWN - NLM
STAT- MEDLINE
DCOM- 20190415
LR  - 20190415
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 393
IP  - 10175
DP  - 2019 Mar 9
TI  - Excess mortality and cardiovascular disease risk in type 1 diabetes.
PG  - 985
LID - S0140-6736(18)33047-2 [pii]
LID - 10.1016/S0140-6736(18)33047-2 [doi]
FAU - Costacou, Tina
AU  - Costacou T
AD  - Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15213, USA. 
      Electronic address: costacout@edc.pitt.edu.
FAU - Guo, Jingchuan
AU  - Guo J
AD  - Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15213, USA.
FAU - Miller, Rachel G
AU  - Miller RG
AD  - Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15213, USA.
FAU - Orchard, Trevor J
AU  - Orchard TJ
AD  - Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15213, USA.
LA  - eng
PT  - Letter
PT  - Comment
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
SB  - AIM
SB  - IM
CON - Lancet. 2018 Aug 11;392(10146):477-486. PMID: 30129464
CIN - Lancet. 2019 Mar 9;393(10175):985-986. PMID: 30860049
MH  - Age of Onset
MH  - *Cardiovascular Diseases
MH  - Cohort Studies
MH  - *Diabetes Mellitus, Type 1
MH  - *Diabetes Mellitus, Type 2
MH  - Humans
MH  - Young Adult
EDAT- 2019/03/13 06:00
MHDA- 2019/04/16 06:00
CRDT- 2019/03/13 06:00
PHST- 2018/08/24 00:00 [received]
PHST- 2018/11/26 00:00 [accepted]
PHST- 2019/03/13 06:00 [entrez]
PHST- 2019/03/13 06:00 [pubmed]
PHST- 2019/04/16 06:00 [medline]
AID - S0140-6736(18)33047-2 [pii]
AID - 10.1016/S0140-6736(18)33047-2 [doi]
PST - ppublish
SO  - Lancet. 2019 Mar 9;393(10175):985. doi: 10.1016/S0140-6736(18)33047-2.

PMID- 30860049
OWN - NLM
STAT- MEDLINE
DCOM- 20190415
LR  - 20190415
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 393
IP  - 10175
DP  - 2019 Mar 9
TI  - Excess mortality and cardiovascular disease risk in type 1 diabetes - Authors'
      reply.
PG  - 985-986
LID - S0140-6736(18)33061-7 [pii]
LID - 10.1016/S0140-6736(18)33061-7 [doi]
FAU - Rawshani, Araz
AU  - Rawshani A
AD  - Department of Molecular and Clinical Medicine, Institute of Medicine, University 
      of Gothenburg, Gothenburg, Sweden.
FAU - Sattar, Naveed
AU  - Sattar N
AD  - Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow 
      G12 8TA, UK. Electronic address: naveed.sattar@glasgow.ac.uk.
FAU - Franzen, Stefan
AU  - Franzen S
AD  - The Swedish National Diabetes Register, Vastra Gotalandsregionen, Gothenburg,
      Sweden.
FAU - Rawshani, Aidin
AU  - Rawshani A
AD  - Sahlgrenska University Hospital, Gothenburg, Sweden.
FAU - Gudbjornsdottir, Soffia
AU  - Gudbjornsdottir S
AD  - The Swedish National Diabetes Register, Vastra Gotalandsregionen, Gothenburg,
      Sweden.
LA  - eng
PT  - Letter
PT  - Comment
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
SB  - AIM
SB  - IM
CON - Lancet. 2019 Mar 9;393(10175):984-985. PMID: 30860047
CON - Lancet. 2019 Mar 9;393(10175):985. PMID: 30860050
CON - Lancet. 2018 Aug 11;392(10146):477-486. PMID: 30129464
MH  - *Cardiovascular Diseases
MH  - *Diabetes Mellitus, Type 1
MH  - Humans
EDAT- 2019/03/13 06:00
MHDA- 2019/04/16 06:00
CRDT- 2019/03/13 06:00
PHST- 2018/10/19 00:00 [received]
PHST- 2018/11/26 00:00 [accepted]
PHST- 2019/03/13 06:00 [entrez]
PHST- 2019/03/13 06:00 [pubmed]
PHST- 2019/04/16 06:00 [medline]
AID - S0140-6736(18)33061-7 [pii]
AID - 10.1016/S0140-6736(18)33061-7 [doi]
PST - ppublish
SO  - Lancet. 2019 Mar 9;393(10175):985-986. doi: 10.1016/S0140-6736(18)33061-7.

PMID- 30860047
OWN - NLM
STAT- MEDLINE
DCOM- 20190415
LR  - 20190415
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 393
IP  - 10175
DP  - 2019 Mar 9
TI  - Excess mortality and cardiovascular disease risk in type 1 diabetes.
PG  - 984-985
LID - S0140-6736(18)33050-2 [pii]
LID - 10.1016/S0140-6736(18)33050-2 [doi]
FAU - Snaith, Jennifer R
AU  - Snaith JR
AD  - Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, NSW 2145,
      Australia; Garvan Institute of Medical Research, Sydney, NSW, Australia.
      Electronic address: jennifer.snaith@health.nsw.gov.au.
FAU - Holmes-Walker, Deborah J
AU  - Holmes-Walker DJ
AD  - Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, NSW 2145,
      Australia.
FAU - Girgis, Christian M
AU  - Girgis CM
AD  - Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, NSW 2145,
      Australia; Department of Diabetes and Endocrinology, Royal North Shore Hospital, 
      University of Sydney, Sydney, NSW, Australia; Westmead Institute for Medical
      Research, University of Sydney, Sydney, NSW, Australia.
FAU - Greenfield, Jerry R
AU  - Greenfield JR
AD  - Garvan Institute of Medical Research, Sydney, NSW, Australia; Department of
      Diabetes and Endocrinology, St Vincent's Hospital, Faculty of Medicine,
      University of New South Wales, Sydney, NSW, Australia.
LA  - eng
PT  - Letter
PT  - Comment
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
SB  - AIM
SB  - IM
CON - Lancet. 2018 Aug 11;392(10146):477-486. PMID: 30129464
CIN - Lancet. 2019 Mar 9;393(10175):985-986. PMID: 30860049
MH  - Age of Onset
MH  - *Cardiovascular Diseases
MH  - Cohort Studies
MH  - *Diabetes Mellitus, Type 1
MH  - *Diabetes Mellitus, Type 2
MH  - Humans
MH  - Young Adult
EDAT- 2019/03/13 06:00
MHDA- 2019/04/16 06:00
CRDT- 2019/03/13 06:00
PHST- 2018/08/22 00:00 [received]
PHST- 2018/11/26 00:00 [accepted]
PHST- 2019/03/13 06:00 [entrez]
PHST- 2019/03/13 06:00 [pubmed]
PHST- 2019/04/16 06:00 [medline]
AID - S0140-6736(18)33050-2 [pii]
AID - 10.1016/S0140-6736(18)33050-2 [doi]
PST - ppublish
SO  - Lancet. 2019 Mar 9;393(10175):984-985. doi: 10.1016/S0140-6736(18)33050-2.

PMID- 30860028
OWN - NLM
STAT- In-Process
LR  - 20190413
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 393
IP  - 10175
DP  - 2019 Mar 9
TI  - Involuntary choreiform movements in a diabetic patient.
PG  - 1033
LID - S0140-6736(19)30304-6 [pii]
LID - 10.1016/S0140-6736(19)30304-6 [doi]
FAU - Xiao, Fei
AU  - Xiao F
AD  - Department of Neurology, Chongqing Key Laboratory of Neurology, The First
      Affiliated Hospital of Chongqing Medical University, Chongqing, China.
FAU - Liu, Mengqi
AU  - Liu M
AD  - Department of Radiology, The First Affiliated Hospital of Chongqing Medical
      University, Chongqing, China.
FAU - Wang, Xue-Feng
AU  - Wang XF
AD  - Department of Neurology, Chongqing Key Laboratory of Neurology, The First
      Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic
      address: 405034986@qq.com.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
EDAT- 2019/03/13 06:00
MHDA- 2019/03/13 06:00
CRDT- 2019/03/13 06:00
PHST- 2018/07/07 00:00 [received]
PHST- 2019/02/04 00:00 [accepted]
PHST- 2019/03/13 06:00 [entrez]
PHST- 2019/03/13 06:00 [pubmed]
PHST- 2019/03/13 06:00 [medline]
AID - S0140-6736(19)30304-6 [pii]
AID - 10.1016/S0140-6736(19)30304-6 [doi]
PST - ppublish
SO  - Lancet. 2019 Mar 9;393(10175):1033. doi: 10.1016/S0140-6736(19)30304-6.